This innovative approach uses genetically modified T-cells to target CLL cells. While currently more established in other blood cancers, ongoing research aims to adapt these therapies for CLL patients. These therapies offer the potential for long-term treatment-free remission, some patients beyond 5 years, although challenges such as toxicity and manufacturing remain.

Learn more about current CAR T-cell therapies available for CLL patients here.

Current research on CAR T-cells is focused on improving their efficacy so that they last longer in the body with fewer side effects. 

• This is particularly important in blood cancers like CLL, where this therapy might be given in later stages of the CLL when patients might be frail or have other health conditions that might make them ineligible for cell therapy as we know it.

"Off-the-shelf" (allogeneic) CAR therapies are being developed to use donor T-cells or NK-cells instead of the patient's own, making them a more readily available option for patients and overcoming some of the challenges associated with traditional CAR T-cell therapy.

• Continue reading: “Off-the-Shelf" CAR T-Cell Therapy for CLL